PharmaTimes1d
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...
PharmaTimes2d
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
PharmaTimes4d
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
PharmaTimes4d
Poolbeg Pharma presents positive results for POLB 001
The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...
PharmaTimes8d
Teva’s Ajovy shows positive results in preventing pediatric migraines
Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...
PharmaTimes8d
NICE endorses Neuraxpharm’s ublituximab for treating MS
Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...
PharmaTimes9d
Antag Therapeutics secures €80 million in weight loss therapy financing
Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...
PharmaTimes9d
Everest therapy shows promise in nephropathy trial
Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...